| Translational activation of snail1 and other developmentally regulated transcription factors by YB-1 promotes an epithelial-mesenchymal transition V Evdokimova, C Tognon, T Ng, P Ruzanov, N Melnyk, D Fink, A Sorokin, ... Cancer cell 15 (5), 402-415, 2009 | 540 | 2009 |
| Nucleocytoplasmic transport of proteins AV Sorokin, ER Kim, LP Ovchinnikov Biochemistry (Moscow) 72, 1439-1457, 2007 | 350 | 2007 |
| Akt-mediated YB-1 phosphorylation activates translation of silent mRNA species V Evdokimova, P Ruzanov, MS Anglesio, AV Sorokin, LP Ovchinnikov, ... Molecular and cellular biology 26 (1), 277-292, 2006 | 321 | 2006 |
| Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation DS Hong, VK Morris, B El Osta, AV Sorokin, F Janku, S Fu, MJ Overman, ... Cancer discovery 6 (12), 1352-1365, 2016 | 234 | 2016 |
| Proteasome system of protein degradation and processing AV Sorokin, ER Kim, LP Ovchinnikov Biochemistry (Moscow) 74, 1411-1442, 2009 | 221 | 2009 |
| Proteasome‐mediated cleavage of the Y‐box‐binding protein 1 is linked to DNA‐damage stress response AV Sorokin, AA Selyutina, MA Skabkin, SG Guryanov, IV Nazimov, ... The EMBO journal 24 (20), 3602-3612, 2005 | 196 | 2005 |
| Structural organization of mRNA complexes with major core mRNP protein YB-1 MA Skabkin, OI Kiselyova, KG Chernov, AV Sorokin, EV Dubrovin, ... Nucleic acids research 32 (18), 5621-5635, 2004 | 195 | 2004 |
| Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG S1406) S Kopetz, KA Guthrie, VK Morris, HJ Lenz, AM Magliocco, D Maru, Y Yan, ... Journal of Clinical Oncology 39 (4), 285, 2021 | 181 | 2021 |
| The proteolytic YB-1 fragment interacts with DNA repair machinery and enhances survival during DNA-damaging stress ER Kim, AA Selyutina, IA Buldakov, V Evdokimova, LP Ovchinnikov, ... Cell Cycle 12 (24), 3791–3803, 2013 | 82 | 2013 |
| MEMO1, a new IRS1-interacting protein, induces epithelial–mesenchymal transition in mammary epithelial cells AV Sorokin, J Chen Oncogene 32 (26), 3130-3138, 2013 | 76 | 2013 |
| Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidates for targeted treatment H Sun, S Cao, RJ Mashl, CK Mo, S Zaccaria, MC Wendl, SR Davies, ... Nature communications 12 (1), 5086, 2021 | 71 | 2021 |
| Протеасомная система деградации и процессинга белков АВ Сорокин, ЕР Ким, ЛП Овчинников Успехи биологической химии 49, 3-76, 2009 | 63 | 2009 |
| Defining the protein-protein interaction network of the human protein tyrosine phosphatase family X Li, KM Tran, KE Aziz, AV Sorokin, J Chen, W Wang Molecular & Cellular Proteomics 15 (9), 3030-3044, 2016 | 55 | 2016 |
| Modeling of patient-derived xenografts in colorectal cancer A Katsiampoura, K Raghav, ZQ Jiang, DG Menter, A Varkaris, MP Morelli, ... Molecular cancer therapeutics 16 (7), 1435-1442, 2017 | 45 | 2017 |
| KRASG12C-independent feedback activation of wild-type RAS constrains KRASG12C inhibitor efficacy MB Ryan, O Coker, A Sorokin, K Fella, H Barnes, E Wong, P Kanikarla, ... Cell reports 39 (12), 2022 | 41 | 2022 |
| Phase IB study of vemurafenib in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with BRAFV600E mutation. Cancer Discov. 2016; 6: 1352 … DS Hong, VK Morris, B El Osta, AV Sorokin, F Janku, S Fu, MJ Overman, ... DOI: https://doi. org/10.1158/2159-8290. CD-16-0050. PMID: https://www. ncbi …, 0 | 40 | |
| Intracellular localization and content of YB-1 protein in multidrug resistant tumor cells AV Vaiman, TP Stromskaya, EY Rybalkina, AV Sorokin, SG Guryanov, ... Biochemistry (Moscow) 71, 146-154, 2006 | 39 | 2006 |
| Platelet metabolism and other targeted drugs; potential impact on immunotherapy P Kanikarla-Marie, M Lam, AV Sorokin, MJ Overman, S Kopetz, ... Frontiers in Oncology 8, 107, 2018 | 30 | 2018 |
| Chromatin state dynamics confers specific therapeutic strategies in enhancer subtypes of colorectal cancer E Orouji, AT Raman, AK Singh, A Sorokin, E Arslan, AK Ghosh, J Schulz, ... Gut 71 (5), 938-949, 2022 | 29 | 2022 |
| Triple blockade of EGFR, MEK and PD-L1 has antitumor activity in colorectal cancer models with constitutive activation of MAPK signaling and PD-L1 overexpression S Napolitano, N Matrone, AL Muddassir, G Martini, A Sorokin, V De Falco, ... Journal of Experimental & Clinical Cancer Research 38, 1-18, 2019 | 29 | 2019 |
Scott KopetzUniversity of Texas MD Anderson Cancer CenterDirección de correo verificada de mdanderson.org
